BIOACTIVE SUBSTANCE
NEW MATERIAL:A bioactive substance MP-A produced by a Staphylococcus aureus and having the following properties; Molecular weight: 1X10 dalton(SDS- PAGE method), Bioactivity: significantly high activity of lymphocyte transformation to human peripheral blood mononuclear cyte, production of interleuki...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KOYAMAISHI YOSHIHIRO MIZUKOSHI MIKIO MIYAKOSHI HIDEO SUGIMOTO MASAZUMI |
| description | NEW MATERIAL:A bioactive substance MP-A produced by a Staphylococcus aureus and having the following properties; Molecular weight: 1X10 dalton(SDS- PAGE method), Bioactivity: significantly high activity of lymphocyte transformation to human peripheral blood mononuclear cyte, production of interleukin-2, cytotoxicity and induction of IgG production, Solubility: soluble at >=pH4 and precipitate at |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JPH02150291A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPH02150291A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JPH02150291A3</originalsourceid><addsrcrecordid>eNrjZBB28vR3dA7xDHNVCA51Cg5x9HN25WFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8V4BHgZGhqYGRpaGjsbEqAEAYnYegg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>BIOACTIVE SUBSTANCE</title><source>esp@cenet</source><creator>KOYAMAISHI YOSHIHIRO ; MIZUKOSHI MIKIO ; MIYAKOSHI HIDEO ; SUGIMOTO MASAZUMI</creator><creatorcontrib>KOYAMAISHI YOSHIHIRO ; MIZUKOSHI MIKIO ; MIYAKOSHI HIDEO ; SUGIMOTO MASAZUMI</creatorcontrib><description>NEW MATERIAL:A bioactive substance MP-A produced by a Staphylococcus aureus and having the following properties; Molecular weight: 1X10 dalton(SDS- PAGE method), Bioactivity: significantly high activity of lymphocyte transformation to human peripheral blood mononuclear cyte, production of interleukin-2, cytotoxicity and induction of IgG production, Solubility: soluble at >=pH4 and precipitate at <=pH3.5, Adsorptivity: adsorbed on strong ion exchanger. USE:A remedy of severe infectious diseases, virus infectious diseases, malignant tumor, etc. PREPARATION:For example, Staphylococcus aureus Cowan III type is cultured and the bacterium is crushed using an ultrasonic disintegrator followed by centrifugation for separation of the supernatant. The separated supernatant is ultrafiltrated for concentration and the resultant concentrated solution is dialyzed and subsequently subjected to the affinity chromatography method using a human IgG-bonded agarose column to collect the non-adsorbed fraction. To the obtained non-adsorbed fraction ammonium sulfate is added and the resultant precipitate is collected and redissolved. The obtained solution is fractionated using a strong ion exchange column for purification, thus obtaining the objective bioactive substance MP-A.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; ENZYMOLOGY ; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROCESSES USING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>1990</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19900608&DB=EPODOC&CC=JP&NR=H02150291A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19900608&DB=EPODOC&CC=JP&NR=H02150291A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KOYAMAISHI YOSHIHIRO</creatorcontrib><creatorcontrib>MIZUKOSHI MIKIO</creatorcontrib><creatorcontrib>MIYAKOSHI HIDEO</creatorcontrib><creatorcontrib>SUGIMOTO MASAZUMI</creatorcontrib><title>BIOACTIVE SUBSTANCE</title><description>NEW MATERIAL:A bioactive substance MP-A produced by a Staphylococcus aureus and having the following properties; Molecular weight: 1X10 dalton(SDS- PAGE method), Bioactivity: significantly high activity of lymphocyte transformation to human peripheral blood mononuclear cyte, production of interleukin-2, cytotoxicity and induction of IgG production, Solubility: soluble at >=pH4 and precipitate at <=pH3.5, Adsorptivity: adsorbed on strong ion exchanger. USE:A remedy of severe infectious diseases, virus infectious diseases, malignant tumor, etc. PREPARATION:For example, Staphylococcus aureus Cowan III type is cultured and the bacterium is crushed using an ultrasonic disintegrator followed by centrifugation for separation of the supernatant. The separated supernatant is ultrafiltrated for concentration and the resultant concentrated solution is dialyzed and subsequently subjected to the affinity chromatography method using a human IgG-bonded agarose column to collect the non-adsorbed fraction. To the obtained non-adsorbed fraction ammonium sulfate is added and the resultant precipitate is collected and redissolved. The obtained solution is fractionated using a strong ion exchange column for purification, thus obtaining the objective bioactive substance MP-A.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>ENZYMOLOGY</subject><subject>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROCESSES USING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1990</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBB28vR3dA7xDHNVCA51Cg5x9HN25WFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8V4BHgZGhqYGRpaGjsbEqAEAYnYegg</recordid><startdate>19900608</startdate><enddate>19900608</enddate><creator>KOYAMAISHI YOSHIHIRO</creator><creator>MIZUKOSHI MIKIO</creator><creator>MIYAKOSHI HIDEO</creator><creator>SUGIMOTO MASAZUMI</creator><scope>EVB</scope></search><sort><creationdate>19900608</creationdate><title>BIOACTIVE SUBSTANCE</title><author>KOYAMAISHI YOSHIHIRO ; MIZUKOSHI MIKIO ; MIYAKOSHI HIDEO ; SUGIMOTO MASAZUMI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JPH02150291A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1990</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>ENZYMOLOGY</topic><topic>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROCESSES USING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>KOYAMAISHI YOSHIHIRO</creatorcontrib><creatorcontrib>MIZUKOSHI MIKIO</creatorcontrib><creatorcontrib>MIYAKOSHI HIDEO</creatorcontrib><creatorcontrib>SUGIMOTO MASAZUMI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KOYAMAISHI YOSHIHIRO</au><au>MIZUKOSHI MIKIO</au><au>MIYAKOSHI HIDEO</au><au>SUGIMOTO MASAZUMI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>BIOACTIVE SUBSTANCE</title><date>1990-06-08</date><risdate>1990</risdate><abstract>NEW MATERIAL:A bioactive substance MP-A produced by a Staphylococcus aureus and having the following properties; Molecular weight: 1X10 dalton(SDS- PAGE method), Bioactivity: significantly high activity of lymphocyte transformation to human peripheral blood mononuclear cyte, production of interleukin-2, cytotoxicity and induction of IgG production, Solubility: soluble at >=pH4 and precipitate at <=pH3.5, Adsorptivity: adsorbed on strong ion exchanger. USE:A remedy of severe infectious diseases, virus infectious diseases, malignant tumor, etc. PREPARATION:For example, Staphylococcus aureus Cowan III type is cultured and the bacterium is crushed using an ultrasonic disintegrator followed by centrifugation for separation of the supernatant. The separated supernatant is ultrafiltrated for concentration and the resultant concentrated solution is dialyzed and subsequently subjected to the affinity chromatography method using a human IgG-bonded agarose column to collect the non-adsorbed fraction. To the obtained non-adsorbed fraction ammonium sulfate is added and the resultant precipitate is collected and redissolved. The obtained solution is fractionated using a strong ion exchange column for purification, thus obtaining the objective bioactive substance MP-A.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_JPH02150291A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | BIOACTIVE SUBSTANCE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A25%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KOYAMAISHI%20YOSHIHIRO&rft.date=1990-06-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJPH02150291A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |